Risk of Infection in Patients With Inflammatory Bowel Disease Treated With Interleukin-Targeting Agents: A Systematic Review and Meta-Analysis.

Konstantinos OuranosHira SaleemStephanos VassilopoulosAthanasios VassilopoulosEvangelia K MylonaFadi ShehadehMarkos KalligerosBincy P AbrahamEleftherios Mylonakis

Published in: Inflammatory bowel diseases (2024)

There was no difference in risk of infection between patients with IBD who received IL-targeting agents compared with the control group. Case registries and randomized controlled trials reporting the safety of IL inhibitors should provide detailed information about the risk of specific infectious complications in patients with IBD receiving IL-targeting agents.

Keyphrases

patients with inflammatory bowel disease
cancer therapy
randomized controlled trial
emergency department
risk factors
clinical trial
systematic review
healthcare
drug delivery
ulcerative colitis
health information
study protocol
newly diagnosed
social media